Recently, Valiant Pharmaceutical’s first active pharmaceutical ingredient (API), olmesartan medoxomil, successfully passed the rigorous review of the European Directorate for the Quality of Medicines and HealthCare (EDQM) and obtained the Certificate of Suitability to the European Pharmacopoeia (CEP), supported by its advanced and independently developed research and production process.

On March 12, Liao Jiasheng, Chairman of CECEP, met with Zeng Yuqun, Chairman and CEO of CATL, and his delegation at CECEP headquarters.

Recently, the Ministry of Industry and Information Technology concluded the public review of the latest list of national-level green manufacturing entities.